Reslizumab intravenous (IV) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.66 [0.43, 1.02]4 studies · 1659 participantsHigh